Neurocrine Biosciences Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $161.6M | $15.0M | $19.8M | $0 | $2.9M | $53.1M | $77.4M | $33.5M |
| Cost of Revenue | $1.3M | $0 | $0 | — | — | — | — | — |
| Gross Profit | $160.4M | $15.0M | $19.8M | — | — | — | — | — |
| Gross Margin | 99.2% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $121.8M | $94.3M | $81.5M | $46.4M | $39.2M | $37.2M | $31.0M | $31.2M |
| SG&A Expense | $169.9M | $68.1M | $32.5M | $18.0M | $13.3M | $13.4M | $12.5M | $13.3M |
| Operating Income | $-131.4M | $-147.4M | $-94.2M | $-64.4M | $-49.7M | $1.4M | $33.9M | $-13.7M |
| Operating Margin | -81.3% | -982.5% | -476.5% | — | -1,701.9% | 2.7% | 43.8% | -41.0% |
| Interest Expense | $19.5M | $0 | $0 | — | — | — | — | — |
| Pretax Income | $-142.5M | $-141.1M | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-142.5M | $-141.1M | $-88.9M | $-60.5M | $-46.1M | $5.0M | $37.6M | $-8.0M |
| Net Margin | -88.2% | -940.6% | -449.8% | — | -1,579.0% | 9.5% | 48.5% | -23.8% |
| EPS (Basic) | $-1.62 | $-1.63 | $-1.05 | $-0.81 | $-0.69 | $0.08 | $0.68 | $-0.15 |
| EPS (Diluted) | $-1.62 | $-1.63 | $-1.05 | $-0.81 | $-0.69 | $0.08 | $0.67 | $-0.15 |
| Shares Outstanding (Basic) | 88.1M | 86.7M | 84.5M | 74.6M | 67.0M | 65.6M | 55.2M | 52.8M |
| Shares Outstanding (Diluted) | 88.1M | 86.7M | 84.5M | 74.6M | 67.0M | 66.9M | 56.3M | 52.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |